The separate roles of endothelin receptors participate in remodeling of matrix metalloproteinase and connexin 43 of cardiac fibroblasts in maladaptive response to isoproterenol

European Journal of Pharmacology

Volumn 634, Issue 1-3, 2010, Pages 101-106

  Peng, Hong Jun ^a   Dai, De Zai ^a   Ji, Hui ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cardiac fibroblast; Connexin43; Endothelin receptor antagonist; Isoproterenol; Matrix metalloproteinase; NADPH oxidase

Indexed keywords

1 BUTYL 3 [2,4 DIS (4 CHLOROBENZYLOXY)PHENYL]PYRAZOLE 5 CARBOXYLIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; CONNEXIN 43; CPU 0213; ENDOTHELIN 1 [11-21]; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ISOPRENALINE; MATRIX METALLOPROTEINASE; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG POTENCY; FIBROBLAST; GENE OVEREXPRESSION; HEART FUNCTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRESS; UPREGULATION; AGONISTS; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; HEART MUSCLE; METABOLISM; NEWBORN; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; CONNEXIN 43; DIOXOLES; FIBROBLASTS; ISOPROTERENOL; MATRIX METALLOPROTEINASES; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONISTS;

EID: 77951205577     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.001     Document Type: Article

References (44)

1. Ahmed S.H., Clark L.L., Pennington W.R., Webb C.S., Bonnema D.D., Leonardi A.H., McClure C.D., Spinale F.G., Zile M.R. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006, 113:2089-2096.
2. Atance J., Yost M.J., Carver W. Influence of the extracellular matrix on the regulation of cardiac fibroblast behavior by mechanical stretch. J. Cell Physiol. 2004, 200:377-386.
3. Batlle M., Perez-Villa F., Garcia-Pras E., Lazaro A., Orus J., Roque M., Roig E. Down-regulation of matrix metalloproteinase-9 (MMP-9) expression in the myocardium of congestive heart failure patients. Transpl. Proc. 2007, 39:2344-2346.
4. Berthoud V.M., Beyer E.C. Oxidative stress, lens gap junctions, and cataracts. Antioxid. Redox Signal. 2009, 11:339-353.
5. Cheng Y.S., Dai D.Z., Dai Y. Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213. Acta. Pharmacol. Sin. 2009, 30:1099-1106.
6. Clozel M., Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann. Med. 2005, 37:2-12.
7. B receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. Clin. Exp. Pharmacol. Physiol. 2009, 36:169-175.
8. B of compound 0213. J. Chinese Pharm. Univ. 2004, 35:552-557.
9. Dong F., Zhang X., Ren J. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension 2006, 47:222-229.
10. Feng Y., Dai D.Z., Na T., Cui B., Wang T., Zhang Y., Dai Y. Endothelin receptor antagonist CPU0213 suppresses ventricular fibrillation in l-thyroxin induced cardiomyopathy. Pharmacol. Rep. 2007, 59:306-314.
11. Feng Y., Tang X.Y., Dai D.Z., Dai Y. Reversal of isoproterenol-induced downregulation of phospholamban and FKBP12.6 by CPU0213-mediated antagonism of endothelin receptors. Acta. Pharmacol. Sin. 2007, 28:1746-1754.
12. Ge Y., Bagnall A., Stricklett P.K., Webb D., Kotelevtsev Y., Kohan D.E. Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am. J. Physiol. Ren. Physiol. 2008, 295:F1635-F1640.
13. Husse B., Briest W., Homagk L., Isenberg G., Gekle M. Cyclical mechanical stretch modulates expression of collagen I and collagen III by PKC and tyrosine kinase in cardiac fibroblasts. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R1898-R1907.
14. ++ current in ventricular cardiomyocytes. J. Pharmacol. Exp. Ther. 1998, 286:662-669.
15. Knezl V., Bacova B., Kolenova L., Mitasikova M., Weismann P., Drimal J., Tribulova N. Distinct lethal arrhythmias susceptibility is associated with sex-related difference in myocardial connexin-43 expression. Neuro. Endocrinol. Lett. 2008, 29:798-801.
16. Kohl P. Heterogeneous cell coupling in the heart: an electrophysiological role for fibroblasts. Circ. Res. 2003, 93:381-383.
17. Kohl P., Camelliti P., Burton F.L., Smith G.L. Electrical coupling of fibroblasts and myocytes: relevance for cardiac propagation. J. Electrocardiol. 2005, 38:45-50.
18. Li L., Chu Y., Fink G.D., Engelhardt J.F., Heistad D.D., Chen A.F. Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension. Hypertension 2003, 42:997-1003.
19. Li N., Jia N., Dai D.Z., Dai Y. Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon. Eur. J. Pharmacol. 2008, 591:211-218.
20. Liu Q., Dai D.Z. Novel endothelin receptor antagonist CPU0213 suppresses expression of MMPs and TIMPs in hypertrophied myocardium caused by l-thyroxin. Chin. J. Clin. Pharmacol. Ther. 2004, 9:281-284.
21. Liu H.R., Tang X.Y., Dai D.Z., Dai Y. Ethanol extracts of Rehmannia complex (Di Huang) containing no Corni fructus improve early diabetic nephropathy by combining suppression on the ET-ROS axis with modulate hypoglycemic effect in rats. J. Ethnopharmacol. 2008, 118:466-472.
22. Maguire J.J., Davenport A.P. The therapeutic potential of PD156707 and related butenolide endothelin antagonists. Expert. Opin. Investig. Drugs 1999, 8:71-88.
23. Malla N., Sjoli S., Winberg J.O., Hadler-Olsen E., Uhlin-Hansen L. Biological and pathobiological functions of gelatinase dimers and complexes. Connect. Tissue Res. 2008, 49:180-184.
24. Na T., Dai D.Z., Tang X.Y., Dai Y. Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017. Naunyn Schmiedebergs Arch. Pharmacol. 2007, 375:39-49.
25. Poelzing S., Akar F.G., Baron E., Rosenbaum D.S. Heterogeneous connexin43 expression produces electrophysiological heterogeneities across ventricular wall. Am. J. Physiol. 2004, 286:H2001-H2009.
26. Polyakova V., Miyagawa S., Szalay Z., Risteli J., Kostin S. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J. Cell Mol. Med. 2008, 12:189-208.
27. Qi M.Y., Xia H.J., Dai D.Z., Dai Y. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. J. Cardiovasc. Pharmacol. 2006, 47:729-735.
28. Quan X.Q., Bai R., Lu J.G., Patel C., Liu N., Ruan Y., Chen B.D., Ruan L., Zhang C.T. Pharmacological enhancement of cardiac gap junction coupling prevents arrhythmias in canine LQT2 model. Cell Commun. Adhes. 2009, 23:1-10.
29. Rich S., McLaughlin V.V. Endothelin receptor blockers in cardiovascular disease. Circulation 2003, 108:2184-2190.
30. Rodrigo R., Vinay J., Castillo R., Cereceda M., Asenjo R., Zamorano J., Araya J., Castillo-Koch R., Espinoza J., Larrain E. Use of vitamins C and E as a prophylactic therapy to prevent postoperative atrial fibrillation. Int. J. Cardiol. 2009, 14. Epub ahead of print.
31. Roldan V., Marin F., Gimeno J.R., Ruiz-Espejo F., Gonzalez J., Feliu E. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am. Heart J. 2008, 156:85-91.
32. Saffitz J.E., Douglas P. Zipes Lecture. Biology and pathobiology of cardiac connexins: from cell to bedside. Heart Rhythm 2006, 3:102-107.
33. Schulz R., Heusch G. Connexin 43 and ischemic preconditioning. Cardiovasc. Res. 2004, 62:335-344.
34. Shimano M., Shibata R., Inden Y., Yoshida N., Uchikawa T., Tsuji Y., Murohara T. Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation. Heart Rhythm 2009, 6:935-940.
35. Wang H.L., Dai D.Z., Gao E., Zhang Y.P., Lu F. Dispersion of ventricular mRNA of RyR2 and SERCA2 associated with arrhythmogenesis in rats. Acta. Pharmacol. Sin. 2004, 25:738-743.
36. Xia H.J., Dai D.Z., Dai Y. Up-regulated inflammatory factors endothelin, NFkappaB, TNFalpha and iNOS involved in exaggerated cardiac arrhythmias in l-thyroxine-induced cardiomyopathy are suppressed by darusentan in rats. Life Sci. 2006, 79:1812-1819.
37. Xu J., Li N., Dai D.Z., Yu F., Dai Y. The endothelin receptor antagonist CPU0213 is more effective than aminoguanidine to attenuate isoproterenol-induced vascular abnormality by suppressing overexpression of NADPH oxidase, ETA, ETB, and MMP9 in the vasculature. J. Cardiovasc. Pharmacol. 2008, 52:42-48.
38. Xu M., Dai D.Z., Dai Y. Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in rats. Am. J. Nephrol. 2009, 29:252-256.
39. Yamakaw K., Kitamura K., Nonoguchi H., Takasu N., Miller R.T., Tomita K. Galpha13 induces preproET-1 gene expression via JNK. Hypertens. Res. 2002, 25:427-432.
40. Yan-ping H., Lian-you Z., Qiang-sun Z., Shao-wei L., Xiao-yan Z., Xiao-long L. Mitogenic effect of arginine vasopressin on adult rat cardiac fibroblast: involvement of PKC-erk1/2 pathway. J. Cardiovasc. Pharmacol. 2008, 52:72-81.
41. Yu F., Dai D.Z., An L.F., Guo X.F. Heart hypertrophy induced by levothyroxine aggravates ischemic lesions and reperfusion arrhythmias in rats. Zhong guo yao li xue bao 1997, 18:71-74. fromer name for Acta Pharmacol Sin.
42. Zhang Y., Huang Z.J., Dai D.Z., Feng Y., Na T., Tang X.Y., Dai Y. Downregulated FKBP12.6 expression and upregulated endothelin signaling contribute to elevateddiastolic calcium and arrhythmogenesis in rat cardiomyopathy produced by l-thyroxin. Int. J. Cardiol. 2008, 130:463-471.
43. Zhang Q., Liu H.R., Ying H.J., Dai D.Z., Tang X.Y., Dai Y. Strontium fructose 1, 6-diphosphate alleviates early diabetic testopathy by suppressing abnormal testicular matrix metalloproteinase system in streptozocin-treated rats. J. Pharm. Pharmacol. 2009, 61:229-236.
44. Zhong J.Q., Zhang W., Gao H., Li Y., Zhong M., Li D., Zhang C., Zhang Y. Changes in connexin 43, metalloproteinase and tissue inhibitor of metalloproteinase during tachycardia-induced cardiomyopathy in dogs. Eur. J. Heart Fail. 2007, 9:23-29.